Skip to main content
TipRanks
Go Ultimate75% OFF

Starpharma Holdings Limited (SPL) Share Price & Analysis

24 Followers

SPL Stock Chart & Stats

A$0.43A$0.00(0.00%)
At close: 4:00 PM GMT+11
AU$0.4AU$0.6AU$0.8Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
AUD 0.42 - AUD 0.44
52-Week Range
AUD 0.31 - AUD 0.88
Previous Close
AUD 0.43
Volume
N/A
Average Volume (3M)
1.83M
Market Cap
AUD 205.24M
Enterprise Value
AUD 284.34M
Total Cash (Recent Filing)
AUD 11.02M
Total Debt (Recent Filing)
AUD 707.00K
Price to Earnings (P/E)
―
Beta
1.68
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Lower Leverage

Debt has fallen from A$8.3m in 2023 to A$0.7m in 2026, materially reducing leverage and financial risk. This gives Starpharma greater balance-sheet flexibility than before while it works toward profitability and manages ongoing development requirements.

Improving Cash Burn

Operating cash flow improved to -A$3.2m and free cash flow to -A$3.5m in 2026, a notable reduction in burn from prior years. Although cash generation remains negative, sustained improvement could extend funding runway and reduce capital pressure.

Gross Profit Generation

Starpharma reported A$12.1m of revenue and A$10.4m of gross profit in 2026, showing that its commercial activities generate substantial gross contribution. That base can support investment in the platform, although operating and net losses remain.

Bears Say

Persistent Operating Losses

EBIT and EBITDA have been negative across all years shown, while 2026 net income was -A$7.5m. Persistent operating losses indicate the business has not yet reached breakeven, limiting internally funded reinvestment and requiring future performance improvement.

Negative Free Cash Flow

Operating cash flow and free cash flow are negative every year shown, with 2026 still at -A$3.2m and -A$3.5m respectively. Continued cash outflows mean Starpharma is not self-funding and may require additional funding unless profitability improves.

Eroding Equity Base

Stockholders’ equity declined from A$62.3m in 2021 to A$13.8m in 2026, while total assets also fell materially. This erosion reduces the balance sheet’s capacity to absorb further losses and constrains flexibility for development and commercialization.

Starpharma Holdings Limited News

SPL FAQ

What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest share price was AU$0.31 and its highest was AU$0.88 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is AU$205.24M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Aug 25, 2026. The company reported -AU$0.02 earnings per share for the quarter.
Is Starpharma Holdings Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 482,911,040 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of -AU$0.02 in its last earnings report. Following the earnings report the stock price went down -0.685%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in AU:SPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology